Pediatric Bacterial Meningitis Surveillance in Niger: Increased Importance of Neisseria meningitidis Serogroup C, and a Decrease in Streptococcus pneumoniae Following 13-Valent Pneumococcal Conjugate Vaccine Introduction

被引:10
|
作者
Hama, Mamadou Kourna [1 ]
Khan, Dam [2 ]
Laouali, Boubou [1 ]
Okoi, Catherine [2 ]
Yam, Abdoulaye [3 ]
Haladou, Moussa [3 ]
Worwui, Archibald [2 ]
Ndow, Peter Sylvanus [2 ]
Obama, Ricardo Nse [3 ]
Mwenda, Jason M. [4 ]
Biey, Joseph [4 ]
Ntsama, Bernard [5 ]
Kwambana-Adams, Brenda A. [2 ]
Antonio, Martin [2 ,6 ]
Senghore, Madikay
Usuf, Effua
Uzochukwu, Egere
Zaman, Akram
Gehre, Florian
Tientcheu, Leopold
Mohammed, Nuredin Ibrahim
Dube, Felix
Ndow, Peter
Sambou, Suso
Jarju, Sheikh
Khan, Dam [2 ]
Chinelo, Ebruke
Bancroft, Rowan
机构
[1] Lab Hop Natl Niamey, Niamey, Niger
[2] London Sch Hyg & Trop Med, Med Res Council Unit Gambia, Collaborating Ctr New Vaccines Surveillance, WHO, London, England
[3] WHO Country Off, Niamey, Niger
[4] WHO Reg Off Africa, Brazzaville, Rep Congo
[5] WHO Intercountry Support Team West Africa, Ouagadougou, Burkina Faso
[6] Univ Warwick, Warwick Med Sch, Microbiol & Infect Unit, Coventry, W Midlands, England
关键词
meningitis; Niger; cerebrospinal fluid; N; meningitidis; S; pneumoniae; HAEMOPHILUS-INFLUENZAE; ANTIMICROBIAL RESISTANCE; MENINGOCOCCAL SEROGROUP; PHYLOGENETIC ANALYSIS; DISEASE; EPIDEMIC; OUTBREAK; NIAMEY; ASSAY; TOOL;
D O I
10.1093/cid/ciz598
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Meningitis is endemic in Niger. Haemophilus influenzae type b (Hib) vaccine and the 13-valent pneumococcal conjugate vaccine (PCV13) were introduced in 2008 and 2014, respectively. Vaccination campaign against Neisseria meningitidis serogroup A was carried out in 2010-2011. We evaluated changes in pathogen distribution using data from hospital-based surveillance in Niger from 2010 through 2016. Methods. Cerebrospinal fluid (CSF) specimens from children <5 years old with suspected meningitis were tested to detect vaccine-preventable bacterial pathogens. Confirmatory identification and serotyping/grouping of Streptococcus pneumoniae, N. meningitidis, and H. influenzae were done. Antimicrobial susceptibility testing and whole genome sequencing were performed on S. pneumoniae isolates. Results. The surveillance included 2580 patients with suspected meningitis, of whom 80.8% (2085/2580) had CSF collected. Bacterial meningitis was confirmed in 273 patients: 48% (131/273) was N. meningitidis, 45% (123/273) S. pneumoniae, and 7% (19/273) H. influenzae. Streptococcus pneumoniae meningitis decreased from 34 in 2014, to 16 in 2016. PCV13 serotypes made up 88% (7/8) of S. pneumoniae meningitis prevaccination and 20% (5/20) postvaccination. Neisseria meningitidis serogroup C (NmC) was responsible for 59% (10/17) of serogrouped N. meningitidis meningitis. Hib caused 67% (2/3) of the H. influenzae meningitis isolates serotyped. Penicillin resistance was found in 16% (4/25) of S. pneumoniae isolates. Sequence type 217 was the most common lineage among S. pneumoniae isolates. Conclusions. Neisseria meningitidis and S. pneumoniae remain important causes of meningitis in children in Niger. The decline in the numbers of S. pneumoniae meningitis post-PCV13 is encouraging and should continue to be monitored. NmC is the predominant serogroup causing N. meningitidis meningitis.
引用
收藏
页码:S133 / S139
页数:7
相关论文
共 50 条
  • [31] Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children
    Tseng, Hung Fu
    Sy, Lina S.
    Liu, In-Lu Amy
    Qian, Lei
    Marcy, S. Michael
    Weintraub, Eric
    Yih, Katherine
    Baxter, Roger
    Glanz, Jason M.
    Donahue, James
    Naleway, Allison
    Nordin, James
    Jacobsen, Steven J.
    VACCINE, 2013, 31 (22) : 2578 - 2583
  • [32] Streptococcus pneumoniae colonization after introduction of 13-valent pneumococcal conjugate vaccine for US adults 65 years of age and older, 2015-2016
    Milucky, Jennifer
    Carvalho, Maria de Gloria
    Rouphael, Nadine
    Bennett, Nancy M.
    Talbot, H. Keipp
    Harrison, Lee H.
    Farley, Monica M.
    Walston, Jeremy
    Pimenta, Fabiana
    Lessa, Fernanda C.
    Bower, Mary
    McNair, Nina
    Williams, Sabrina
    Presmanes, Emily
    Tunali, Amy
    Thomas, Stephanie
    Hollick, Rosemary
    Langdon, Jacqueline
    Sepehri, Amir Salar
    Sharova, Anna
    VACCINE, 2019, 37 (08) : 1094 - 1100
  • [33] Commentary on paradoxical observations pertaining to the impact of the 13-valent pneumococcal conjugate vaccine on serotype 3 Streptococcus pneumoniae infections in children
    De Wals, Philippe
    VACCINE, 2018, 36 (37) : 5495 - 5496
  • [34] Pediatric Invasive Pneumococcal Disease in Taiwan Following a National Catch-up Program With the 13-Valent Pneumococcal Conjugate Vaccine
    Wei, Sung-Hsi
    Chiang, Chuen-Sheue
    Chiu, Cheng-Hsun
    Chou, Pesus
    Lin, Tzou-Yien
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (03) : E71 - E77
  • [35] Molecular surveillance of pneumococcal carriage following completion of immunization with the 13-valent pneumococcal conjugate vaccine administered in a 3+1 schedule
    Syrogiannopoulos, George A.
    Grivea, Ioanna N.
    Moriondo, Maria
    Nieddu, Francesco
    Michoula, Aspasia N.
    Calabrese, Maria Rita
    Anthracopoulos, Michael
    Azzari, Chiara
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [36] Longitudinal characterization of nasopharyngeal colonization with Streptococcus pneumoniae in a South African birth cohort post 13-valent pneumococcal conjugate vaccine implementation
    Dube, Felix S.
    Ramjith, Jordache
    Gardner-Lubbe, Sugnet
    Nduru, Polite
    Robberts, F. J. Lourens
    Wolter, Nicole
    Zar, Heather J.
    Nicol, Mark P.
    SCIENTIFIC REPORTS, 2018, 8
  • [37] Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era
    Zuccotti, Gianvincenzo
    Mameli, Chiara
    Daprai, Laura
    Garlaschi, Maria Laura
    Dilillo, Dario
    Bedogni, Giorgio
    Faccini, Marino
    Gramegna, Maria
    Torresani, Erminio
    Emanuela, Ballerini
    Annarita, Benincaso
    Milena, Bonvissuto
    Dorella, Bricalli
    Manuela, Brioschi
    Simona, Calloni Cinzia
    Irene, Camiletti Marina
    Giacomo, Colella
    Laura, De Angelis
    Silvia, Decarlis
    Francesca, Di Nello
    Massimiliano, Dozzi
    Erica, Galli
    Vera, Gandini
    Grazia, Giuliani Maria
    Franca, Laviola
    Barbara, Loda
    Maddalena, Macedoni
    Elisabetta, Mazzucchi
    Gabriella, Metta Maria
    Anna, Moscatiello
    Pilar, Nannini
    Mariangela, Petruzzi
    Damiano, Picicco
    Michela, Picciotti
    Stefania, Pisanelli
    Norberto, Porta
    Giulia, Ramponi
    Francesca, Redaelli
    Riccardo, Rubini
    Natascia, Sala
    Vincenzo, Saitta
    Giuseppina, Scelza
    Maria, Tiso Rosa
    Mariangela, Tomasetto
    Matteo, Torcoletti
    Marta, Travaini
    Maurizio, Valentini
    Chiara, Vessia
    VACCINE, 2014, 32 (05) : 527 - 534
  • [38] A case report of parapneumonic pleural effusion caused by Streptococcus pneumoniae serotype 19A in a child immunized with 13-valent conjugate pneumococcal vaccine
    Diawara, Idrissa
    Zerouali, Khalid
    Elmdaghri, Naima
    Abid, Abderrahman
    BMC PEDIATRICS, 2017, 17
  • [39] Distribution of 13-Valent Pneumococcal Conjugate Vaccine Streptococcus pneumoniae Serotypes in US Adults Aged ≥50 Years With Community-Acquired Pneumonia
    Sherwin, Robert L.
    Gray, Sharon
    Alexander, Ronika
    McGovern, Paul C.
    Graepel, Jay
    Pride, Michael W.
    Purdy, Jay
    Paradiso, Peter
    File, Thomas M., Jr.
    JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (11) : 1813 - 1820
  • [40] One-Step Multiplex PCR Assay for Detecting Streptococcus pneumoniae Serogroups/Types Covered by 13-Valent Pneumococcal Conjugate Vaccine (PCV13)
    Coskun-Ari, Fatma Filiz
    Guldemir, Dilek
    Durmaz, Riza
    PLOS ONE, 2012, 7 (12):